Neues aus der lectinologie

Deutsche Apotheker Zeitung

Volumn 140, Issue 17, 2000, Pages 41-56

  Rüdiger, Harold ^a   Gabius, Sigrun ^c   Gabius, Hans Joachim ^b  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c Onkologische Schwerpunktpraxis   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

LECTIN;

DNA MODIFICATION; FOOD HANDLING; IMMUNOMODULATION; PROTEIN DETERMINATION; PROTEIN FAMILY; RESEARCH; REVIEW; TRANSGENE;

EID: 0034720171     PISSN: 00119857     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (94)

1. Enserink, M.: Institute copes with genetic hot potato. Science 281, 1124-1125 (1999).
2. Enserink, M.: Preliminary data touch off genetic food fight. Science 283, 1094-1095 (1999).
3. Dickson, D.: UK debates public's role in science advice. Nature 399, 188 (1999).
4. Loder, N.: Royal Society: GM food hazard claim is 'flawed'. Nature 399, 188 (1999).
5. Rüdiger, H., H.-J. Gabius: Lectinologie. Dtsch. Apoth. Ztg. 133, 2371-2381 (1993).
6. Sharon, N.: Glycoproteins now and then: a personal account. Acta Anat. 161, 7-17 (1998).
7. Rüdiger, H., H.-C. Siebert, D. Solís, J. Jiménez-Barbero, A. Romero, C.-W. von der Lieth, T. Díaz-Mauriño, H.-J. Gabius: Medicinal chemistry based on the sugar code: Fundamentals of lectinology and experimental strategies with lectins as targets. Curr. Med. Chem. 7, 389-416 (2000).
8. Reuter, G., H.-J. Gabius: Proteinglykosylierung. Dtsch. Apoth. Ztg. 137, 1319-1335 (1997).
9. Siebert, H.-C., C.-W. von der Lieth, H.-J. Gabius: Der Zuckercode. Dtsch. Apoth. Ztg. 139, 272-282 (1999).
10. Avery, O.T., C. M. MacLeod, M. McCarty: Studies on the chemical nature of the substance inducing transformation of pneumococcal types. J. Exp. Med. 79, 137-158 (1944).
11. Varki, A., J. Marth: Oligosaccharides in vertebrate development. Sem. Dev. Biol. 6, 127-138 (1995).
12. Brockhausen, I., H. Schachter: Glycosyltransferases involved in N- and O-glycan biosynthesis. In: H.-J. Gabius, S. Gabius (Hrsg.): Glycosciences: Status and Perspectives, S. 79-113, Chapman & Hall, London 1997.
13. Oriol, R., R. Mollicone, A. Cailleau, L. Balanzino, C. Breton: Divergent evolution of fucosyltransferase genes from vertebrates, invertebrates and bacteria. Glycobiology 9, 323-334 (1999).
14. Reuter, G., H.-J. Gabius: Eukaryotic glycosylation - whim of nature or multipurpose tool? Cell Mol. Life Sci. 55, 368-422 (1999).
15. Schachter, H. (Hrsg.): Molecular basis of glycoconjugate disease. Biochim. Biophys. Acta 1455, 61-62 (1999).
16. Laine, R. A.: The information-storing potential of the sugar code. In: H.-J. Gabius, S. Gabius (Hrsg.): Glycosciences: Status and Perspectives, S. 1-14, Chapman & Hall, London 1997.
17. Gabius, H.-J.: The how and why of protein-carbohydrate interaction: a primer to the theoretical concept and a guide to application in drug design. Pharm. Res. 15, 23-30 (1998).
18. Gabius, H.-J., A. Bardosi: Neoglycoproteine. Dtsch. Apoth. Ztg. 134, 1964-1971 (1994).
19. Gabius, H.-J., S. Gabius (Hrsg.): Glycosciences: Status and Perspectives. Chapman & Hall, London 1997.
20. Gabius, H.-J.: Animal lectins. Eur. J. Biochem. 243, 543-576 (1997).
21. Gabius, H.-J., F. Sinowatz (Hrsg.): Special volume on glycosciences. Acta Anat. 161, 1-276 (1998).
22. Kaltner, H., B. Stierstorfer: Animal lectins as cell adhesion molecules. Acta Anat. 161, 162-179 (1998).
23. Rüdiger, H.: Plant lectins - More than just tools for glycoscientists: Occurrence, structure and possible functions of plant lectins. Acta Anat. 161, 130-152 (1998).
24. Galanina, O. E., H. Kaltner, L. S. Khraltsova, N. V. Bovin, H.-J. Gabius: Further refinement of the description of the ligand-binding characteristics for the galactoside-binding mistletoe lectin, a plant agglutinin with immunomodulatory potency. J. Mol. Recogn. 10, 139-147 (1997).
25. Gabius, S., H.-J. Gabius: Mistelextrakte in der Krebstherapie. Pharm. Ztg. 143, 2101-2117 (1998).
26. Luther, P., H. Becker: Die Mistel - Botanik, Lektine, medizinische Anwendungen. VEB Verlag Volk und Gesundheit, Berlin 1986.
27. Rüdiger, H., G. Fleischmann: "Kalorienblocker" und deren "Wirkung". Dtsch. Apoth. Ztg. 123, 697-698 (1983).
28. Ryder, S. D., J. A. Smith, J. M. Rhodes: Peanut lectin: a mitogen for normal human colonic epithelium and human HT29 colorectal cancer cells. J. Natl. Cancer Inst. 84, 1410-1416 (1992).
29. Wang, Q., L.-G. Yu, B. J. Campbell, J. D. Milton, J. M. Rhodes: Identification of intact peanut lectin in peripheral venous blood. Lancet 352, 1831-1832 (1998).
30. Powell, K. S., A. M. R. Gatehouse, V. A. Hilder, J. A. Gatehouse: Antifeedant effects of plant lectins and an enzyme on the adult stage of the rice brown planthopper, Nilaparvata lugens. Entomol. Exp. Appl. 75, 51-59 (1995).
31. Down, R. E., A. M. R. Gatehouse, W. D. O. Hamilton, J. A. Gatehouse: Snowdrop lectin inhibits development and decreases fecundity of the glasshouse potato aphid (Aulacorthum solani) when administered in vitro and via transgenic plants both in laboratory and glasshouse trials. Insect Physiol. 42, 1035-1045 (1996).
32. van Damme, E. J. M., A. K. Allen, W. J. Peumans: Isolation and characterization of a lectin with exclusive specificity towards mannose from snowdrop (Galanthus nivalis) bulbs. FEBS Lett. 215, 140-144 (1987).
33. Wright, C. S., G. Hester: The 2.0 Ångstrom structure of a cross-linked complex between snowdrop lectin and a branched mannopentaose: Evidence for two unique binding modes. Structure 4, 1339-1352 (1996).
34. Powell, K. S., J. Spence, M. Bharathi, J. A. Gatehouse, A. M. R. Gatehouse: Immunohistochemical and developmental studies to elucidate the mechanism of action of the snowdrop lectin on the rice brown planthopper, Nilaparvata lugens (Stal). J. Insect Physiol. 44, 529-539 (1998).
35. Gatehouse, A. M. R., G. M. Davison, C. A. Newell, A. Merryweather, W. D. O. Hamilton, E. P. J. Burgess, R. J. C. Gilbert, J. A. Gatehouse: Transgenic potato plants with enhanced resistance to the tomato moth Lacanobia oleracea: Growth room trials. Mol. Breeding 3, 49-63 (1997).
36. Rao, K. V., K. S. Rathore, T. K. Hodges, X. Fu, E. Stoger, D. Sudhakar, S. Williams, P. Christou, M. Bharati, D. P. Bown, K. S. Powell, J. Spence, A. M. R. Gatehouse, J. A. Gatehouse: Expression of snowdrop lectin (GNA) in transgenic rice plants confers resistance to rice brown planthopper. Plant J. 15, 469-477 (1998).
37. Sudhakar, D., X. D. Fu, E. Stoger, S. Williams, J. Spence, D. P. Brown, M. Bharati, J. A. Gatehouse, P. Christou: Expression and immunolocalization of the snowdrop lectin, GNA, in transgenic plants. Transgenic Res. 7, 371-378 (1998).
38. Stoger, E., S. Williams, P. Christou, R. E. Down, J. A. Gatehouse: Expression of the insecticidal lectin from snowdrop (Galanthus nivalis agglutinin; GNA) in transgenic wheat plants: Effects on predation by the grain aphid Sitobion avenae. Mol. Breeding 5, 65-73 (1999).
39. Tang, K. X., P. Tinjuangjun, Y. Xu, X. F. Sun, J. A. Gatehouse, P. C. Ronald, H. X. Qi, X. G. Lu, P. Christou, A. Kohli: Particle bombardment-mediated co-transformation of elite Chinese rice cultivars with genes conferring resistance to bacterial blight and sapsuckinc insect pests. Planta 208, 552-563 (1999).
40. Welters, P., K. Hollrichter: Novel Food erobert den Markt. BIO-Forum 7-8, 445-447 (1999).
41. Beringer, J. E.: Cautionary tale on safety of GM crops. Nature 399, 405 (1999).
42. Losey, J. E., L. S. Rayor, M. E. Carter: Transgenic pollen harms monarch larvae. Nature 399, 214 (1999).
43. Birch, A. N. E., I. E. Geoghegan, M. E. N. Majerus, J. W. McNicol, C. A. Hackett, A. M. R. Gatehouse, J. A. Gatehouse: Tri-trophic interaction involving pest aphids, predatory 2-spot ladybirds and transgenic potatoes expressing snowdrop lectin for aphid resistance. Mol. Breeding 5, 75-83 (1999).
44. Bell, H. A., E. C. Fitches, R. E. Down, G. C. Marris, J. P. Edwards, J. A. Gatehouse, A. M. R. Gatehouse: The effect of snowdrop lectin (GNA) delivered via artificial diet and transgenic plants on Eulophus pennicornis (Hymenoptera: Eulophidae), a parasitoid of the tomato moth Lacanobia oleracea (Lepidoptera: Noctuidae). J. Insect Physiol. 45, 983-991 (1999).
45. Ewen, S. W., A. Pusztai: Effect of diets containing genetically modified potatoes expressing Galanthus nivalis lectin on rat small intestine. Lancet 354, 1353-1354 (1999).
46. Horton, R.: Genetically modified foods: "absurd" concern or welcome dialogue? Lancet 345, 1314-1315 (1999).
47. Kuiper, H. A., H. P. J. M. Noteborn, Ad. A. C. M. Peijnenburg: Adequacy of methods for testing the safety of genetically modified foods. Lancet 345, 1315-1316 (1999).
48. Brown, P.: Lancet editor defends decision to publish GM research paper. Br. Med. J. 319, 1089 (1999).
49. Gabius, S., K. Kayser, H.-J. Gabius: Mistelextrakte und ihre Anwendung: wissenschaftlich betrachtet. Münch. Med. Wochenschr. 137, 602-606 (1995).
50. Hajto, T., K. Hostanska, H.-J. Gabius: Modulatory potency of the galactoside-specific lectin from mistletoe extract (Iscador®) on the host defence system in vivo in rabbits and patients. Cancer Res. 49, 4803-4808 (1989).
51. Hajto, T., K. Hostanska, K. Frei, C. Rordorf, H.-J. Gabius: Increased secretion of tumor necrosis factor-α, interleukin-1, and interleukin-6 by human mononuclear cells exposed to β-galactoside-specific lectin from clinically applied mistletoe extracts. Cancer Res. 50, 3322-3326 (1990).
52. Gabius, S., S. S. Joshi, K. Kayser, H.-J. Gabius: The galactoside-specific lectin from mistletoe as biological response modifier. Int. J. Oncol. 1, 705-708 (1992).
53. Schlodder, D.: Die Mistel in der Krebstherapie: Möglichkeiten und Grenzen. Paracelsus report Heft 2, 2-8 (1994).
54. Leroi, R.: Der Ätherleib zwischen Kosmos und Erde. In: Freie Hochschule für Geisteswissenschaften am Goetheanum (Hrsg.): Beiträge zu einer Erweiterung der Heilkunst nach geisteswissenschaftlichen Erkenntnissen, S. 1-10, R. Steiner Verlag, Dornach 1982.
55. Gabius, H.-J., S. Gabius: Anthroposophie und Naturwissenschaft. Die Mistel im Spagat. Dtsch. Ärztebl. 93, A810 (1996).
56. Burkhard, B.: Mistel: Gestaltung eines Mythos; Mistel: rationale Pharmakotherapie? Pharm. Ztg. 143, 1650-1656, 1848-1855 (1998).
57. Burkhard, B.: "Unkonventionelle" Medizin: was Politik und Gerichte sagen. Münch. Med. Wochenschr. 140, 733-737 (1998).
58. Burkhard, B.: Begutachtung "unkonventioneller" Maßnahmen bei malignen Tumorerkrankungen in der gesetzlichen Krankenversicherung. Der med. Sachverständige 95, 110-116 (1999).
59. Angell, M., J. P. Kassirer: Alternative medicine - the risks of untested and unregulated remedies. N. Engl. J. Med. 339, 839-841 (1998).
60. Sogn, J. A.: Tumor immunology: the glass is half full. Immunity 9, 757-763 (1998).
61. Gabius, S., H.-J. Gabius: Immunmodulierende Misteltherapie durch Lektinstandardisierung: ein zweischneidiges Schwert? Versicherungsmedizin 51, 128-136 (1999).
62. Scala, G., I. Quinto, M. R. Ruocco, A. Arcucci, M. Mallardo, P. Caretto, G. Forni, S. Venuta: Expression of an exogenous interleukin-6 gene in human Epstein Barr virus B cells confers growth advantage and in vivo tumorigenicity. J. Exp. Med. 172, 61-68 (1990).
63. Suematsu, S., T. Matsusaka, T. Matsuda, S. Ohno, J. Miyazaki, K. Yamamura, T. Hirano, T. Kishimoto: Generation of plasmocytomas with the chromosomal translocation t (12; 15) in interleukin-6 transgenic mice. Proc. Natl. Acad. Sci. USA 89, 232-235 (1992).
64. Schirmacher, P., M. Peters, G. Ciliberto, M. Blessing, J. Lotz, K. H. Meyer zum Büschenfelde, S. Rose-John: Hepatocellular hyperplasia, plasmocytoma formation, and extramedullary hematopoiesis in interleukin (IL)-6/soluble IL-6 receptor double-transgenic mice. Am. J. Pathol. 153, 639-648 (1998).
65. Hilbert, D. M., M. Kopf, B. A. Mock, G. Köhler, S. Rudikoff: Interleukin-6 is essential for in vivo development of B lineage neoplasms. J. Exp. Med. 182, 243-248 (1995).
66. Lattanzio, G., C. Libert, M. Aquilina, M. Cappelletti, G. Ciliberto, P. Musiani, V. Poli: Defective development of pristane-oil-induced plasmacytomas in interleukin-6-deficient BALB/c mice. Am. J. Pathol. 151, 689-696 (1997).
67. Lu, C., C. Sheehan, J. W. Rak, C. A. Chambers, N. Hozumi, R. S. Kerbel: Endogenous interleukin-6 can function as an in vivo growth-stimulatory factor for advanced-stage human melanoma cells. Clin. Cancer Res. 2, 1417-1425 (1996).
68. Mckenzie, R. C., E.-S. Park, W. R. Brown, G. S. Shivji, D. N. Sauder: Effect of ultraviolet-inducible cytokines on melanoma growth in vivo: stimulation of melanoma growth by interleukin-1 and -6. Photodermatol. Photoimmunol. Photomed. 10, 74-79 (1994).
69. Moore, R. J., D. M. Owens, G. Stamp, C. Arnott, F. Burke, N. East, H. Holdsworth, L. Turner, B. Rollins, M. Pasparakis, G. Kollias, F. Balkwill: Mice deficient in tumor necrosis factor-α are resistant to skin carcinogenesis. Nature Med. 5, 828-831 (1999).
70. Oshika, Y., M. Nakamura, Y. Abe, Y. Fukuchi, M. Yoshimura, M. Itoh, Y. Ohnishi, T. Tokunaga, Y. Fukushima, H. Hatanaka, H. Kijima, H. Yamazaki, N. Tamaoki, Y. Ueyama: Growth stimulation of non-small cell lung cancer xenografts by granulocyte-macrophage colony-stimulating factor (GM-CSF). Eur. J. Cancer 34, 1958-1961 (1998).
71. Reichner, J. S., J. A. Mulligan, R. Spisni, E. A. Sotomayor, J. E. Albina, K. I. Bland: Effect of IL-6 overexpression on the metastatic potential of rat hepatocellular carcinoma cells. Ann. Surg. Oncol. 5, 279-286 (1997).
72. Gelin, J., L. L. Moldawer, C. Lönnroth, B. Sherry, R. Chizzonite, K. Lundholm: Role of endogenous tumor necrosis factor-α and interleukin-1 for experimental tumor growth and the development of cancer cachexia. Cancer Res. 51, 415-421 (1991).
73. Ravoet, C., J. De Greve, K. Vandewoude, J. Kerger, J.-P. Sculier, P. Lacor, P. Stryckmans, M. Piccart: Tumor stimulating effects of recombinant human interleukin-6. Lancet 344, 1576-1577 (1994).
74. Costes, V., J. Liautard, M.-C. Picot, M. Robert, N. Lequeux, J. Brochier, P. Baldet, J.-F. Rossi: Expression of the interleukin-6 receptor in primary renal cell carcinoma. J. Clin. Pathol. 50, 835-840 (1997).
75. Jin, L., R. Q. Yuan, A. Fuchs, Y. Yao, A. Joseph, R. Schwall, S. J. Schnitt, A. Guida, H. M. Hastings, J. Andres, G. Turkel, P. J. Polverini, I. D. Goldberg, E. M. Rosen: Expression of interleukin-1β in human breast carcinoma. Cancer 80, 421-434 (1997).
76. Strassmann, G., M. Fong, J. S. Kenney, C. O. Jacob: Evidence for the involvement of interleukin-6 in experimental cancer cachexia. J. Clin. Invest. 89, 1681-1684 (1992).
77. O'Riordain, M. G., J. S. Falconer, J. Maingay, K. C. H. Fearon, J. A. Ross: Peripheral blood cells from weight-losing cancer patients control the hepatic acute phase response by a primarily interleukin-6-dependent mechanism. Int. J. Oncol. 15, 823-827 (1999).
78. Jones, S. A., D. Novick, S. Horiuchi, N. Yamamoto, A. J. Szalai, G. M. Fuller: C-reactive protein: a physiological activator of interleukin-6 receptor shedding. J. Exp. Med. 189, 599-604 (1999).
79. Kunze, E., H. Schulz, H. Ahrens, H.-J. Gabius: Lack of an antitumoral effect of immunomodulatory galactoside-specific mistletoe lectin on N-methyl-N-nitrosourea-induced urinary bladder carcinogenesis in rats. Exp. Toxicol. Pathol. 49, 167-180 (1997).
80. Kunze, E., H. Schulz, H.-J. Gabius: Inability of galactoside-specific mistletoe lectin to inhibit N-methyl-N-nitrosourea-induced tumor development in the urinary bladder of rats and to mediate a local cellular immune response after long-term administration. J. Cancer Res. Clin. Oncol. 124, 73-87 (1998).
81. Kunze, E., H. Schulz, M. Adamek, H.-J. Gabius: Long-term administration of galactos-ide-specific mistletoe lectin in an animal model: no protection against N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder carcinogenesis in rats and no induction of a relevant local cellular immune response. J. Cancer Res. Clin. Oncol. 126, 125-138 (2000).
82. Gabius, H.-J., F. Darro, M. Remmelink, S. André, J. Kopitz, A. Danguy, S. Gabius, I. Salmon, R. Kiss: Evidence for stimulation of tumor proliferation in cell lines and histotypic cultures by clinically relevant low doses of the galactoside-binding mistletoe lectin, a component of proprietary extracts, im Druck.
83. Heimpel, H.: Leserzuschrift. Tumordiagn. Then 16, 205 (1995).
84. Hagenah, W., I. Dörges, E. Gafumbegete, T. Wagner: Subkutane Manifestation eines zentrozytischen Non-Hodgkin-Lymphoms an Injektionsstellen eines Mistelpräparats. Dtsch. Med. Wochenschr. 123, 1001-1004 (1998).
85. Mayer, H.: Leserbrief. Pharm. Ztg. 141, 2882-2883 (1996).
86. Arzneimittelkommission der deutschen Ärzteschaft: Zu Berichten über unerwünschte Arzneimittelwirkungen nach Behandlung mit Mistelextrakt-haltigen und Organ-/Enzympräparaten bei Tumorerkrankungen. Dtsch. Ärztebl. 94, A1154-1155 (1997).
87. Schönhöfer, P. S., B. Werner, M. Kuklinski, P. Zürner, P. A. Berg, W. Becker-Brüser: Ungewöhnliche Immunerkrankungen durch Pflanzenextrakte (Echinacea, Mistel): Akute Sarkoidose. Arzneimitteltherapie 17, 282-284 (1999).
88. Pressemitteilung: Rekombinantes Mistellektin wichtigstes Projekt bei Madaus. Dtsch. Apoth. Ztg. 139, 493-495 (1999).
89. Hauser, S. P.: Mistel - Wunderkraut oder Medikament? Therapiewoche 43, 76-81 (1993).
90. Kaesi, E.: Unconventional therapies for cancer. 3. Iscador. Can. Med. Ass. J. 158, 1157-1159 (1998).
91. McNamee, D.: Mistletoe extract ineffective in melanoma. Lancet 354, 1101 (1999).
92. Kleijnen, J., P. Knipschild: Mistletoe treatment for cancer. Review of controlled trials in humans. Phytomedicine 1, 255-260 (1994).
93. Sauer, H.: Leserbrief. Onkologe 4, 1180 (1998).
94. Redaktionsbeitrag: Zum Nutzen von Mistelextrakten (Iscador u.a.) bei Krebs. arznei-telegramm Heft 9, 94 (1999).